BUHLMANN News

LabSense News Q1 2020 Edition

In this “Q1 2020 Edition”of BUHLMANN’s LabSense News, we are proud to introduce Quantum Blue^® Anti-Infliximab (RUO) and Anti-Adalimumab (RUO) to the TDM rapid test portfolio. Check out a new video for Flow CAST^® basophil activation test (BAT), view recent BÜHLMANN assay citations, and read an interesting white paper for our BÜHLMANN GanglioCombi^® MAG ELISA.

<span data-mce-type="bookmark" style="display: inline-block; width: 0px; overflow: hidden; line-height: 0;" class="mce_SELRES_start"></span><span data-mce-type="bookmark" style="display: inline-block; width: 0px; overflow: hidden; line-height: 0;" class="mce_SELRES_start"></span><span data-mce-type="bookmark" style="display: inline-block; width: 0px; overflow: hidden; line-height: 0;" class="mce_SELRES_start"></span>

Download WordPress Themes

Download Premium WordPress Themes Free

Download Nulled WordPress Themes

Premium WordPress Themes Download

download udemy paid course for free

download samsung firmware

Download Nulled WordPress Themes

free download udemy paid course

BÜHLMANN Laboratories AG (BL), based in Basel Switzerland, has been discovering, developing & manufacturing innovative chemistry and immunological in-vitro diagnostic (IVD) and research use only (RUO) assays for almost 50 years (circa 1976). As the United States commercial affiliate of BL, BUHLMANN Diagnostics Corp (BDC), based in Amherst, NH is committed to providing exceptional sales, support, and technical services to our clinical, discovery and basic science research laboratory customers.